Kornimate/medical-research-clean huggingface dataset:
effects of sargassum horneri extract on patients with hypersensitivity

Conditions: Skin Hypersensitivity

Summary: the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of sargassum horneri extract in patients with skin hypersensitivity for 12 weeks.

previous studies have indicated that panax ginseng c.a. mey extract may have the ability to improve liver function. therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the sargassum horneri extract in patients with skin hypersensitivity for 12 weeks; the safety of the compound are also evaluate. the investigators examine scorad(scoring of atopic dermatitis) score, pga (patient global assessment) score, iga (investigator global assessment) score, total ige, eosinophil counts, ecp, il-4, il-31, and tarc at baseline, as well as after 6 and 12 weeks of intervention. one hundred adults were administered either 1,000 mg of sargassum horneri extract or a placebo each day for 12 weeks.

Eligibility criteria:
inclusion criteria: * atopy by hanifin \& rajka diagnostic criteria * scorad \< 40 exclusion criteria: * abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dl) * diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dl) * history of viral hepatitis or cancer * uncontrolled hypertension * history of serious cardiac disease such as angina or myocardial infarction * history of gastrectomy * history of medication for psychiatric disease * administration of oriental medicine including herbs within the past 4 weeks
comparison of high intensity strength training and muscle energy techniques in tkr patients

Conditions: Knee Osteoarthritis; Arthroplasty, Knee Replacement; Resistance Training

Summary: globally, the prevalence of total joint replacement (tkr) procedures has been rising, providing patients with better joint function, decreased pain, and enhanced quality of life. a thorough and successful postoperative rehabilitation program, which attempts to restore optimal function and lower the risk of problems related to the treatment, is necessary for the success of total knee replacement (tkr) procedures. after total knee replacement, postoperative rehabilitation is a crucial stage in the patient's healing process. normal knee function is frequently hampered by issues like pain management, muscular weakness, joint stiffness, and proprioceptive deficiencies. therefore, choosing a suitable rehabilitation regimen is crucial.

the main objective of this study is to compare two different rehabilitation strategies: muscle energy techniques with balance exercises and high intensity strength training with balance exercises. the research aims to maximize postoperative results for patients who have undergone total knee replacement surgery. the focus on resistance exercises intended to improve muscle strength and power is what defines high intensity strength training, or hist. research has indicated that hist is beneficial in enhancing joint stability, muscle function, and overall functional outcomes across a range of orthopedic groups. its precise use and effect on patients recovering from tkr surgery, however, need further investigation. in order to increase joint mobility, lessen pain, and improve neuromuscular control, patients who get muscle energy techniques (met) actively participate in targeted muscle contractions. met has demonstrated potential in treating muscular imbalances.

Eligibility criteria:
inclusion criteria: * individuals between the ages of 45 and 75 * patients should be within a certain timeframe following surgery (e.g., post op day 0-day) to ensure homogeneity throughout the rehabilitation phase. * patients who have had primary total knee replacement * to take part in the rct, participants must give informed consent * they must be able and willing to follow the study protocol's instructions for post-rehabilitation care. exclusion criteria: * comorbidities: individuals with significant comorbidities affecting rehabilitation, such as severe cardiovascular disease or neuromuscular disorders, may be excluded. * allergies/contraindications: patients with allergies or contraindications to specific exercises or techniques used in the study. * inadequate cognitive function: participants with cognitive impairments that prevent them from comprehending and adhering to the rehabilitation protocols. * other knee surgeries: patients who have had other knee surgeries or have had bilateral knee replacements may be excluded due to variations in recovery and rehabilitation.

Keywords: total knee replacement knee osteoarthritis strength training muscle energy technique
development of serologic assays for human herpes virus-8

Conditions: Kaposi Sarcoma; HIV Infection

Summary: dr. burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. we would like to apply this technique to develop an assay for detecting antibodies to hhv-8 (kshv, the etiologic agents of kaposi's sarcoma, an aids-defining condition). we initially plan to examine samples from patients with kaposi's sarcoma, since all those patients are almost certainly infected with hhv-8. we are thus using samples from patients with previously diagnosed kaposi's sarcoma. the samples in question are stored at the nci fcrf repository operated by saic frederick or in rockville, md.

our colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of antigens using recombinant proteins. we would like to apply this technique to develop an assay for detecting antibodies to hhv- 8 (kshv, the etiologic agent of kaposi s sarcoma, an aids-defining condition). in addition we would like to potentially measure antibody responses to hiv, other infectious agents, and human antigens, to see if antibodies (or high antibody titers) to these antigens are associated with kaposi s sarcoma or hiv infection. we initially plan to examine samples from patients with kaposi s sarcoma, since all those patients are almost certainly infected with hhv-8. we would subsequently plan to examine samples from hiv positive and hiv negative patients without known kaposi s sarcoma. we are thus requesting permission to use samples from patients with and without previously diagnosed kaposi's sarcoma. in addition to antibody testing, we would also like to examine these samples for evidence of infection with other infectious agents, such as newly identified or unknown viruses, using techniques such as pcr or deep sequencing.

Eligibility criteria:
* data analysis only

Keywords: antibody kaposi's sarcoma hiv kaposi sarcoma
efficacy and safety of prc-4016 in subjects with mixed dyslipidemia

Conditions: Dyslipidemia

Summary: the objective of this study is * to evaluate the efficacy of prc-4016 by assessment of the percentage change in blood lipids and lipoprotein parameter from baseline after 12 weeks of treatment * to evaluate the safety of prc-4016 as assessed by adverse events and other safety parameters

6-8 weeks screening period with diet/lifestyle stabilization and lipid qualification

Eligibility criteria:
main inclusion criteria: * fasting triglycerides 200-499 mg/dl * non-hdl-c \> 130 mg/dl * stable statin treatment exclusion criteria: * type i diabetes or uncontrolled type ii diabetes * recent cardiovascular or coronary event * history of pancreatitis * history or evidence of major and clinically significant diseases that would interfere with the conduct of the study or interpretation of data * uncontrolled hypertension
high-density eeg-meg-wearable eeg: comparison of quantitative electroencephalographic indicators as neurophysiological markers of effectiveness of mindfulness therapy in addition to standard treatment in patients with high-frequency episodic migraine

Conditions: Migraine; Migraine Disease; High Frequency Episodic Migraine

Summary: recent studies suggest that mindfulness may be an effective treatment for migraine, reducing the frequency of attacks, depression, anxiety and improving quality of life. however, the pathophysiological mechanisms underlying the effectiveness are not yet fully known. the identification of neurophysiological markers may help to better understand the mechanisms on which mindfulness acts in migraine sufferers and to develop increasingly targeted and personalized mindfulness interventions to optimize migraine treatment. the main objective of the study is to identify neurophysiological indicators of effectiveness of mindfulness treatment in patients with migraine without high-frequency aura with clinically available devices (meg and hdeeg). another goal is to recognize the indicators also in the signal acquired with wearable devices in home use (weeg). finally, another goal will be to study the relationship between the identified neurophysiological markers and the change in neuropsychological test scores.


Eligibility criteria:
inclusion criteria: * adult patients will be included who fulfil the ichd-3 criteria \[8\] for hfem, code 1.3-chronic migraine (characteristics similar to cm but with a frequency of 8-14 migraine days per month) with stable therapy in the 3 months prior to the start of mindfulness treatment. if the therapy is changed during the screening visit, the patient will wait 3 months before starting mindfulness treatment. exclusion criteria: * in the presence of psychiatric comorbidities in the psychotic area, reported in the history or assessed by the clinician * if pregnant * in the presence of secondary headache comorbidities (e.g. idiopathic intracranial hypertension) * if they have undergone symptomatic abuse detoxification at least twice in the previous two years * if they have already undergone any kind of treatment with mindfulness or meditation techniques

Keywords: migraine meg mindfulness wearable eeg
reducing secondary distress in violence researchers: a randomised trial of the effectiveness of group debriefings.

Conditions: Emotional Distress

Summary: the objectives of the study were: to (1) describe the epidemiology of emotional distress experienced by ugandan violence researchers; to (2) assess the effectiveness of group debriefings in mitigating secondary distress; to (3) assess risk and protective factors. eligible participants were 59 ugandan researchers employed by the good schools study (gss, nct01678846) to interview children and adults who experienced violence. recruited participants were randomly assigned to group debriefings (intervention) or film viewing (control). the primary outcome was change in levels of emotional distress.

background: secondary distress including emotional distress, vicarious trauma (vt) and secondary traumatic stress (sts) due to exposure to primary trauma victims have been described in helping professionals and in violence researchers. to our knowledge, there are few prevalence studies, and no tailored interventions have been tested to reduce secondary distress in violence researchers. objective: to (1) describe the epidemiology of emotional distress experienced by ugandan violence researchers; to (2) assess the effectiveness of group debriefings in mitigating secondary distress; to (3) assess risk and protective factors. methods: an unblinded, individually randomised trial with parallel assignment was conducted. eligible participants were 59 ugandan researchers employed by the good schools study (gss, nct01678846) to interview children and adults who experienced violence in the district of luwero, uganda. 53 researchers agreed to participate and were randomly allocated. the intervention group (n=26) participated in three group debriefings and the control group (n=27) participated in three leisure sessions (film viewing).the primary outcome was change in levels of emotional distress (srq-20); secondary outcomes were levels of vt and sts at end-line.

Eligibility criteria:
inclusion criteria: * eligible participants were all 59 ugandan researchers who had been employed by the gss. exclusion criteria: * none

Keywords: secondary traumatic stress vicarious trauma secondary distress
uterotonic efficacy of oxytocin 2.5 versus 10 units during caesarean section at mulago hospital

Conditions: Adverse Effect of Oxytocic Drugs; Uterine Hemorrhage; Inappropriate Dose of Drug Administered

Summary: the purpose of the study was to determine whether 2.5 international units of oxytocin gives adequate uterine tone and is safe as compared to 10 international units of oxytocin following caesarean section delivery at mulago hospital.


Eligibility criteria:
inclusion criteria: * asa i (healthy patient with no systemic disease) or ii ( mild to moderate systemic disease) * age between 18 to 40 years * singleton pregnancies exclusion criteria: * • allergy to oxytocin * ruptured uterus * significant obstetric disease (including pregnancy induced hypertension, eclampsia,) * known risk factors for postpartum haemorrhage or uterine atony * inherited or acquired coagulation disorder * history of post partum haemorrhage

Keywords: oxytocin uterine tone mulago hospital dose side effects
a rct of the efficacy of tegoprazan 50mg qd in the treatment of helicobacter pylori infection ( tath-1 )

Conditions: Vonoprazan; Helicobacter Pylori Infection; Proton Pump Inhibitor

Summary: the treatment of helicobacter pylori is very important. the routine treatment is quadruple therapy. in recent years, double therapy has appeared and the curative effect is fair. however, antacid generally uses proton pump inhibitor. the proton pump inhibitor needs double dose to achieve good antacid curative effect. the effect of tegoprazan used for inhibiting gastric acid is better than proton pump inhibitor. at present, some studies use tegoprazan instead of common proton pump inhibitor, but almost all use double dose of tegoprazan. in the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 50mg qd of tegoprazan. therefore, in this study, 50mg qd of tegoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of tegoprazan on helicobacter pylori.

the treatment of helicobacter pylori is very important. the routine treatment is quadruple therapy. in recent years, double therapy has appeared and the curative effect is fair. however, antacid generally uses proton pump inhibitor. the proton pump inhibitor needs double dose to achieve good antacid curative effect. the effect of tegoprazan used for inhibiting gastric acid is better than proton pump inhibitor. at present, some studies use tegoprazan instead of common proton pump inhibitor, but almost all use double dose of tegoprazan. in the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 50mg qd of tegoprazan. therefore, in this study, 50mg qd of tegoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of tegoprazan on helicobacter pylori.

Eligibility criteria:
inclusion criteria: 1. patients aged ≥18 years with hp-positive first sterilization were included in this study. 2. before treatment, the existence of helicobacter pylori can be confirmed by one or more of the following methods: rapid urease test, hp culture, 13c urea breath test, 14c urea breath test and stool hp antigen test. exclusion criteria: 1. acute upper gastrointestinal bleeding. 2. active gastric or duodenal ulcer. 3. acute gastric or duodenal mucosal lesions. 4. previous eradication treatment of helicobacter pylori. 5. penicillin/furazolidone allergy. 6. surgery that may affect gastric acid secretion (upper gastrointestinal resection or vagotomy). 7. zollinger-ellison syndrome or other hypergastric acid secretion diseases. 8. severe neurological, cardiovascular, pulmonary, liver,renal, metabolic,gastrointestinal, urological, etc. 9. any fertile woman must use proper contraception.
a study to estimate the effect of formulation on the relative absorption of sb-751689 administered to healthy women

Conditions: Osteoporosis

Summary: this study will examine the effects of formulation on the relative bioavailability of sb-751689 (400 mg) administered to healthy postmenopausal women. subjects will receive a single oral dose of each formulation, with five formulations of sb-751689 tested in total. blood samples will be taken up to 24 hours postdose after each dose administration. this study will provide information for future possible formulation development of sb-751689 for phase iii.


Eligibility criteria:
inclusion criteria: * healthy postmenopausal women; 40 and 65 years of age, inclusive * non-smokers (as defined in exclusion criteria 6 below) * body weight \> or = 50 kg and bmi within the range 19-32 kg/m2 * capable of giving written informed consent and complying with the requirements and restrictions listed in the consent form exclusion criteria: * any clinically relevant biological or physical abnormality found or reported at screening which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study * a qtc interval of \> 450 msec at screening * positive urine drug screen at screening * positive urine test for alcohol at pre-dose * positive for hiv or hepatitis b or c virus at screening * urinary cotinine levels indicative of smoking at screening * history of smoking or use of nicotine containing products within one year of the study or \>10 pack-year history of smoking overall * history of regular alcohol consumption exceeding 7 units/week (1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening * history of drug abuse within 6 months of the study * participation in a clinical study and received a drug or a new chemical entity with 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of the current study medication. * exposure to more than four new chemical entities within 12 months prior to the first dosing day. * use of prescription or non-prescription drugs * consumption of red wine, grapefruit, grapefruit juice or grapefruit containing products within 14 days prior to the first dose of study medication * donation of blood in excess of 500 ml within 56 days prior to dosing * evidence of renal, hepatic or biliary impairment * history of serious gastrointestinal disease * history of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. * history of clinically significant cardiovascular disease * medical conditions that might alter bone metabolism * serum parathyroid hormone (ipth) test levels outside the reference range at screening * liver function tests, parathyroid hormone test or cpk outside the reference range at screening

Keywords: formulation drug study
13c-glucose tracing of tumour and t cells in the ascites of ovarian cancer patients.

Conditions: Ovarian Cancer; Ascites

Summary: the objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. this observational study involves intravenous infusion of \[u-13c\]glucose into patients during standard paracentesis.

participants and location: this study will recruit up to 10 patients of at least 18 years of age with ascites due to diagnosed ovarian cancer. eligible study patients will be screened and recruited at bc cancer - victoria. paracentesis procedure and patient consent will occur at the island health - royal jubilee hospital. study design: participants meeting the inclusion criteria will be fitted with a continuous glucose monitor (freestyle libre) before proceeding to their scheduled appointment for paracentesis. labeled glucose will be administered via i.v. at dose of 8g of labeled glucose in 60 ml over 10 min. this is followed by 4g of labeled glucose in 30 ml over an hour. sample collection and processing: during \[u-13c\]glucose infusions, the ascites specimens will kept on ice. samples will be collected and analyzed by flow cytometry and mass spectrometry for states of metabolism and metabolite profiles respectively. the ascites fluid will be monitored for changes in metabolite levels. \[u-13c\]glucose product information: \[u-13c\]glucose clinical grade will be compound bc cancer pharmacy.

Eligibility criteria:
inclusion criteria: * ovarian cancer * any stage or grade of disease * ascites fluid that requires draining * any treatment regimen * primary or recurrent ascites * understands the concept of the study and give informed consent. exclusion criteria: * participants must not have diabetes or abnormal hemoglobin a1c levels. * the patient's glucose levels must be between 4 - 11.1 mm before administering an infusion. this is to ensure that patients are within normal blood glucose levels, as described by diabetes canada. * participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.
tribel registry: national belgian registry of percutaneous tricuspid valve repair using a transcatheter edge-to-edge repair technique

Conditions: Tricuspid Valve Regurgitation

Summary: in this study, patients who have undergone or will undergo a transcatheter edge-to-edge repair (teer) for tricuspid valve regurgitation (tr) will be followed up for 5 years. the goal of this prospective and retrospective, observational, non-randomized, multicenter registry is to confirm that teer is a feasible, safe and effective treatment option for tr and to evaluate the long-term efficacy and safety of teer. the main endpoints are: * change in tricuspid regurgitation grade: number of patients with a reduction in tricuspid regurgitation score by at least one grade * composite of major adverse event: number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or tia, coronary revascularization, new onset af or ventricular arrhythmia)


Eligibility criteria:
inclusion criteria: * at least 18 years old * eligible for teer procedure * informed consent signed exclusion criteria: * unwilling to provide informed consent